What is William Blair’s Estimate for MRSN Q1 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Investment analysts at William Blair issued their Q1 2025 earnings estimates for shares of Mersana Therapeutics in a research note issued to investors on Monday, March 3rd. William Blair analyst A. Hsieh anticipates that the company will earn ($0.20) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. William Blair also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.22) EPS and FY2027 earnings at ($0.89) EPS.

A number of other equities analysts also recently commented on the stock. Wedbush restated an “outperform” rating and set a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday. Citigroup began coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.25.

Mersana Therapeutics Price Performance

MRSN stock opened at $0.51 on Thursday. The stock has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $1.56. The stock has a market cap of $63.30 million, a PE ratio of -0.84 and a beta of 1.39. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 1 year low of $0.46 and a 1 year high of $6.28.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.

Institutional Investors Weigh In On Mersana Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp bought a new position in shares of Mersana Therapeutics during the fourth quarter worth approximately $131,000. Sphera Funds Management LTD. acquired a new position in shares of Mersana Therapeutics during the fourth quarter worth $987,000. Nuveen Asset Management LLC lifted its holdings in Mersana Therapeutics by 53.6% in the fourth quarter. Nuveen Asset Management LLC now owns 232,223 shares of the company’s stock valued at $332,000 after buying an additional 81,022 shares during the period. Millennium Management LLC lifted its holdings in Mersana Therapeutics by 206.4% in the fourth quarter. Millennium Management LLC now owns 795,973 shares of the company’s stock valued at $1,138,000 after buying an additional 536,190 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Mersana Therapeutics by 12.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,111,998 shares of the company’s stock valued at $1,590,000 after buying an additional 118,952 shares during the period. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.